[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Henan Provincial People's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":553},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,53,83,106,130,158,181,206,230,252,277,299,321,343,363,385,406,428,446,465,483,500,516,533],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100640859","non-invasive-urinary-genomics-based-risk-assessment-for-early-urothelial-carcinoma-diagnosis-100640859",false,"NCT07614594","Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis","Non-invasive Urinary Genomics-Based Risk Assessment for Early Diagnosis of Urothelial Carcinoma","Inclusion Criteria:\n\nPatients are eligible if they meet all of the following criteria:\n\n1. Age ≥ 18 years.\n2. Presence of gross or microscopic hematuria.\n3. Imaging (B-ultrasonography, CT, or MRI) showing a renal pelvic, ureteral, or bladder lesion.\n4. Scheduled for surgery for tissue histopathological diagnosis.\n5. Able to provide written informed consent.\n\nExclusion Criteria\n\n1. Inadequate urine sample (poor quality or insufficient volume).\n2. Lack of final histopathological diagnosis.","ALL","18 Years",{"count":19,"type":20},800,"ESTIMATED","OBSERVATIONAL","This is a two-stage, prospective, single-center observational diagnostic accuracy study evaluating noninvasive urine testing for the detection of urothelial carcinoma (UC). The study enrolls adult patients presenting with gross or microscopic hematuria and imaging evidence of a space-occupying lesion in the renal pelvis, ureter, or bladder, who are scheduled for diagnostic cystoscopy and\u002For surgical tissue sampling. Histopathological examination serves as the reference standard.\n\nStage 1 (Completed, 8th October 2019 - 31st December 2023):\n\nA total of 113 participants have been enrolled. Owing to sufficient research funding, all participants in this stage underwent four urine-based tests: cytology, fluorescence in situ hybridization (FISH), DNA methylation, and a 17-gene mutation panel.\n\nStage 2 (Ongoing, from 1st January 2024):\n\nThe testing protocol was refined to focus on urine DNA methylation alone, owing to limited research funding and the lower cost of DNA methylation compared with the 17-gene mutation panel. As of registration (May 2026), approximately 330 participants have been enrolled.\n\nAll enrolled participants are categorized into two groups based on histopathology: a UC group (including upper tract urothelial carcinoma \\[UTUC\\] and bladder cancer \\[BC\\]) and a non-UC control group. The primary outcome is the diagnostic accuracy (area under the receiver operating characteristic curve \\[AUC\\] with 95% confidence interval, sensitivity, and specificity) of the four urine-based tests in the Stage 1 cohort. The key secondary outcome is the diagnostic accuracy of urine DNA methylation in the Stage 2 cohort. Other secondary outcomes include paired comparisons of AUCs among the four tests in the Stage 1 cohort. Exploratory analyses will include the diagnostic performance of urine cytology in a subset of Stage 2 participants with UTUC, as well as subgroup analyses by tumor site (UTUC vs. BC).\n\nBecause this study is purely observational and non-interventional, prospective registration was not a regulatory or institutional requirement when enrollment began in 2019. This record is being submitted prior to any data analysis to ensure consistency with current research transparency standards.",[24,25,26,27],"Urothelial Carcinoma (UC)","Upper Tract Urothelial Carcinoma","UTUC","Bladder Cancer (BC)",[29,30,31,32,33,34,35,36,37,38,39],"urothelial carcinoma","upper tract urothelial carcinoma","DNA methylation","17 genes mutation","diagnosis","bladder cancer","diagnostic efficacy","urine sample","cytology","fluorescence in situ hybridization","non-invasive detection","RECRUITING","2026-06-30",{"date":43,"type":44},"2026-07-02","ACTUAL",{"date":46,"type":44},"2019-10-08",{"date":48,"type":20},"2030-12-31",{"name":50,"class":51},"Henan Provincial People's Hospital","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":52},"100644750","surface-modified-flow-diverter-for-intracranial-aneurysms-assessment-of-ischemic-and-clinical-outcomes-100644750","NCT07674004","Surface-Modified Flow Diverter for Intracranial Aneurysms: Assessment of Ischemic and Clinical Outcomes","Prospective Randomized Controlled Trial of Surface-Modified Flow Diverter for Intracranial Aneurysms: Multicenter Assessment of Ischemic and Clinical Outcomes","PRISMATIC","Inclusion Criteria:\n\n1. Patients were diagnosed with unruptured intracranial aneurysms, and the lesions were evaluated to be suitable for endovascular treatment with flow diverter devices (PED Shield\u002FLattice).\n2. During the study period, only one target aneurysm per patient was treated, with the exception of segmental lesions, in which multiple aneurysms located within the same arterial segment were treated with a single or overlapping study devices.\n3. The target aneurysm was treated solely with flow diverter (FD) implantation in the current study.\n4. The age of enrolled patients ranged from 18 to 75 years old.\n5. Patients were capable of understanding the study-related informed consent information and provided written informed consent for the use of their clinical data for research purposes.\n\nExclusion Criteria:\n\n1. Patients with a prior history of endovascular treatment for the target aneurysm.\n2. Patients in the acute stage of cerebrovascular diseases (acute cerebral infarction or intracerebral hemorrhage with an onset time of ≤ 2 weeks).\n3. Patients complicated with other cerebrovascular disorders, including moyamoya disease, cerebrovascular malformations, and arteriovenous fistula.\n4. Patients with atherosclerotic changes in the parent artery of the target aneurysm that necessitated additional intraoperative endovascular interventions (e.g., balloon angioplasty or conventional stent implantation).\n5. Patients with a preoperative modified Rankin Scale (mRS) score greater than 2.\n6. Patients with any absolute contraindications to device treatment as specified in the Instructions for Use (IFU).\n7. Patients enrolled in other clinical trials that may interfere with the primary or secondary endpoints of the present study.\n8. Patients with comorbidities that may interfere with neurological function evaluation, affect survival status, or impair the ability to complete follow-up visits.\n9. Pregnant or lactating female patients.","75 Years",{"count":63,"type":20},196,"INTERVENTIONAL",[66],"NA","Flow diverters (FDs) have become a mainstay of endovascular therapy for unruptured intracranial aneurysms (UIAs), yet their implantation carries an inherent risk of ischemic complications. The Pipeline Flex Embolization Device with Shield Technology (PED Shield) and the Lattice Flow Diverter (LFD) are two surface-modified FDs that have shown promising efficacy for mitigating procedure-related ischemic events in prior single-arm or retrospective series. Nevertheless, head-to-head comparative data between these two surface-modified flow diverters remain scarce, and prospective randomized clinical trials are warranted to corroborate their differential performance in lowering ischemic complication risks.This prospective, multicenter randomized controlled trial (RCT) was designed to compare the efficacy of PED Shield versus LFD in reducing ischemic complications after endovascular treatment of UIAs. A total of 196 eligible participants who meet the predefined inclusion and exclusion criteria will be enrolled in the trial. The primary outcome measure is the incidence of new diffusion-weighted imaging (DWI)-positive lesions on brain magnetic resonance imaging (MRI) within 48 hours after the procedure. The secondary outcome measures consist of perioperative symptomatic ischemic events, all-cause mortality and disability rate during the follow-up period, delayed aneurysm rupture at the 6-month follow-up, complete aneurysm occlusion rate, incidence of major in-stent stenosis (stenosis degree \\>50%) at the 6-month follow-up, and the number of new DWI-positive lesions within 48 hours post-procedure.",[69,70],"Intracranial Aneurysms","Flow Diverter",[72,73,74],"intracranial aneurysms","flow dierters","surface-modified","2026-06-29",{"date":77,"type":44},"2026-07-01",{"date":79,"type":44},"2026-05-21",{"date":81,"type":20},"2027-09-30",{"name":50,"class":51},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":89,"minAge":17,"maxAge":61,"enrollmentInfo":90,"targetDuration":4,"studyType":64,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":52},"100612180","effect-of-perioperative-high-dose-transdermal-nicotine-patch-on-pain-sensitivity-among-male-abstinent-tobacco-smokers-undergoing-thoracic-surgery-a-randomized-controlled-pilot-study-100612180","NCT07250230","Effect of Perioperative High-dose Transdermal Nicotine Patch on Pain Sensitivity Among Male Abstinent Tobacco Smokers Undergoing Thoracic Surgery: A Randomized Controlled Pilot Study","Inclusion Criteria:\n\n1. Male, aged 18-75 years, with a body mass index (BMI) of 18-28 kg\u002Fm2 Between;\n2. Thoracoscopic lobectomy\u002Fsegmental\u002Fwedge resection under general anesthesia;\n3. American Society of Anesthesiologists (ASA) classifications I-III Level;\n4. Regular smoking for more than 2 years, smoking more than 10 cigarettes per day in the past 6 months, and not successfully quitting smoking within 1 month (after admission, the doctor and nurse informed the smoking cessation plan to intervene before starting to stop smoking or 1 ≤ cigarette count ≤ 10 cigarettes\u002Fday in the past month), FTND score ≥ 2;\n5. No severe respiratory diseases, no serious cardiovascular and cerebrovascular diseases (hypertension is treated with SBP ≤ 160mmHg, DBP ≤ 90mmHg after systemic treatment);\n6. Obtain informed consent.\n\nExclusion Criteria:\n\n1. Those who have a history of alcoholism, long-term use of sedatives or analgesics;\n2. Patients with psychiatric and nervous system diseases (such as Parkinson's, depression, schizophrenia) and severe audio-visual dysfunction before surgery;\n3. Preoperative systolic blood pressure \\> 180mmHg or diastolic blood pressure \\> 110mmHg;\n4. Patients who were converted to thoracotomy during thoracoscopic surgery\n5. Patients who are transferred to the intensive care unit after surgery;\n6. Patients who refuse to use analgesic pump treatment\u002Fdo not configure the analgesic pump according to regulations;\n7. Patients who have self-removed patches\u002Fshort hospital stay resulting in a postoperative observation time of \\\u003C 48 hours","MALE",{"count":91,"type":20},80,[66],"Globally, approximately 230 million adults undergo surgical procedures each year, with around 30% of patients maintaining smoking habits prior to surgery. Extensive clinical research has confirmed that tobacco exposure is a significant independent risk factor for perioperative complications. Epidemiological data indicate that long-term smokers experience a significantly higher all-cause mortality rate during hospitalization, approximately 20% greater than non-smokers, while the incidence of postoperative complications is 40% higher. Consequently, international guidelines universally recommend the establishment of standardized preoperative smoking cessation programs for surgical patients. Nicotine withdrawal, a typical clinical manifestation during smoking cessation, involves symptoms across multiple systems: neuropsychiatric symptoms such as mood depression, sleep disturbances, and irritability; autonomic dysfunction leading to postural dizziness and bradycardia; and metabolic dysregulation resulting in increased appetite and weight gain. Notably, these withdrawal symptoms exhibit a significant time-dependent pattern, typically peaking 24-72 hours after cessation. Multicenter studies have demonstrated that tobacco-dependent patients experience an average increase of IV Abstract 35-45% in opioid consumption within 24 hours postoperatively, with the duration of analgesic requirements extended by approximately 25%. However, some patients suffer from severe adverse reactions to opioids (e.g., nausea, vomiting, confusion), making the use of adjuvant medications for multimodal analgesia and optimized pain management particularly crucial. By the late 20th century, the analgesic properties of nicotine, a primary component of tobacco, were systematically studied and applied in clinical practice.",[95,96,97],"Nicotine Dependence","Thoracic Diseases","Analgesia","2026-01-20",{"date":100,"type":44},"2026-01-22",{"date":102,"type":44},"2025-11-30",{"date":104,"type":20},"2026-12-31",{"name":50,"class":51},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":112,"sex":16,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":64,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":129,"locationsCount":52},"100548777","application-of-hfnc-for-the-prevention-of-hypoxemia-during-perioperative-anesthetic-induced-intubation-in-children-a-randomized-controlled-clinical-trial-100548777","NCT06425406","Application of HFNC for the Prevention of Hypoxemia During Perioperative Anesthetic-induced Intubation in Children: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age 2-10 years old;\n* American Society of Anesthesiologists (ASA) Level I or II;\n* Children with healthy lungs and hearts;\n* Clear headed and able to cooperate with anesthesiologists for treatment.\n\nExclusion Criteria:\n\n* Contraindications for HFNC: (1) Complete obstruction of the upper respiratory tract; (2) Skull base fracture or nasal bone fracture; (3) Patients who refuse to use HFNC;\n* The American Society of Anesthesiologists (ASA) rating is greater than Level II;\n* Children with upper respiratory tract infections within 2 weeks;\n* Pulmonary dysfunction, congenital heart disease in children;",true,"2 Years","10 Years",{"count":116,"type":20},48,[66],"Compared with adults, children have higher metabolic needs, and the airway is more likely to collapse. Before tracheal intubation after anesthesia induction, the patient 's spontaneous breathing completely disappears. At this critical stage, the residual oxygen of the lung is consumed, resulting in hypoxemia and atelectasis. Therefore, it is necessary to explore the best oxygenation strategy during intubation. In addition, ultrasound has become a common equipment in the operating room. It has the advantages of portability, repeatability, and no radiation, and can provide strong support for the diagnosis of gastric distension.",[120,121,122],"High-flow Nasal Cannula","Children","Pre-oxygenation","2025-11-24",{"date":125,"type":44},"2025-12-01",{"date":127,"type":44},"2024-06-15",{"date":102,"type":20},{"name":50,"class":51},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":112,"sex":16,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":64,"phases":142,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":4},"100601566","efficacy-of-oxalidine-and-sufentanil-in-strabismus-correction-100601566","NCT07112157","Efficacy of Oxalidine and Sufentanil in Strabismus Correction","Efficacy of Oxalidine and Sufentanil in Strabismus Correction: a Non Inferiority Trial","strabismus","Inclusion Criteria:\n\n* The patients to be treated with strabismus correction under general anesthesia are 3-60 years old, regardless of gender.\n\nThe American Society of anesthesiologists (ASA) classification is Ⅰ - Ⅱ. Patients or their guardians (for child patients) voluntarily participated in the trial and signed the informed consent form with informed consent.\n\nExclusion Criteria:\n\n* Those who are allergic to oxalidine, sufentanil or any of the ingredients in their preparations.\n\nPatients with severe heart, liver, kidney and other important organ dysfunction.\n\nHave a history of epilepsy or central nervous system disease. Other opioid analgesics were used within 48 hours before operation. Pregnant or lactating women. Patients with mental disorders who are unable to cooperate to complete the test related assessment.","3 Years","60 Years",{"count":141,"type":20},290,[66],"The purpose of this study is to compare the anesthetic effect of oxalidine and sufentanil in strabismus surgery through a non inferiority test, including analgesic efficacy, intraoperative hemodynamic stability, postoperative recovery quality and the incidence of adverse reactions. . This study will provide a new evidence-based basis for the application of opioids in ophthalmic short surgery, and may improve the perioperative experience of patients.",[145],"Strabismus Surgery",[147,148],"strabismus surgery","analgesia","NOT_YET_RECRUITING","2025-08-01",{"date":152,"type":44},"2025-08-08",{"date":154,"type":20},"2025-08",{"date":156,"type":20},"2026-08",{"name":50,"class":51},{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":112,"sex":16,"minAge":17,"maxAge":61,"enrollmentInfo":165,"targetDuration":4,"studyType":64,"phases":167,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":4},"100600403","analgesic-effect-and-safety-of-oliceridine-and-oxycodone-in-vitrectomy-100600403","NCT07097038","Analgesic Effect and Safety of Oliceridine and Oxycodone in Vitrectomy","Analgesic Effect and Safety of Oliceridine and Oxycodone in Vitrectomy: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18-75 years old, ASA Ⅰ - Ⅱ (the age of patients with vitreous surgery can be relaxed to 75 years old, and serious systemic diseases need to be excluded);\n* Vitrectomy with local anesthesia (retrobulbar \u002F peribulbar block) combined with intravenous sedation and analgesia (such as maculopathy, retinal detachment, etc.);\n* Preoperative VAS score ≤ 3, can cooperate with pain and sedation score;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Be allergic to test drugs or opioids, or have a history of opioid abuse;\n* Severe cardiopulmonary disease (such as heart failure, COPD), liver and kidney dysfunction (alt\u002Fast \\> 3 times normal, creatinine \\> 177 μ mol\u002Fl);\n* Glaucoma (avoiding the risk of fluctuation of intraocular pressure), sinus bradycardia (\\\u003C 50 beats \u002F min, preventing aggravation of oculo cardiac reflex);\n* Used analgesic \u002F sedative drugs within 24 hours before surgery;\n* Those who are unable to cooperate due to mental illness or cognitive impairment.",{"count":166,"type":20},120,[66],"Traditional opioid analgesia is a method to treat moderate to severe pain. However, the use of opioids is not without risks. When treating acute pain, patients may have hypotension, respiratory depression, hypoxia, nausea and vomiting, irritability and pruritus. The aim of this study was to evaluate the analgesic effect and safety of g-protein-biased μ - opioid receptor agonists Oliceridine and oxycodone in vitrectomy.",[170],"Vitrectomy",[172],"Basic anesthesia","2025-07-30",{"date":175,"type":44},"2025-07-31",{"date":177,"type":20},"2025-07",{"date":179,"type":20},"2026-07",{"name":50,"class":51},{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":112,"sex":16,"minAge":139,"maxAge":4,"enrollmentInfo":188,"targetDuration":190,"studyType":21,"phases":4,"briefSummary":191,"conditions":192,"keywords":196,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":4},"100595547","comprehensive-geriatric-assessment-in-chronic-disease-management-for-older-adults-in-china-a-registry-study-cgacdm---older-adults-in-china-100595547","NCT07033871","Comprehensive Geriatric Assessment in Chronic Disease Management for Older Adults in China: A Registry Study （CGACDM - Older Adults in China）","CGACDM - Older","Inclusion Criteria:\n\n* 1\\. Aged 60 years or older 2. Diagnosed with chronic diseases in the circulatory, respiratory, digestive, nervous, or endocrine systems, consistent with corresponding disease diagnostic criteria; 3. Availability of complete medical records; 4. Clear consciousness and ability to independently answer questions; 5. Signed informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Presence of any condition\u002Fcircumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language, psychiatric disturbances).\n\n  2\\. Presence of serious\u002Fsevere co-morbidities in the opinion of the investigator which may limit short term (i.e. 6 month) life expectancy.\n\n  3\\. Current participation in a randomised interventional clinical trial.",{"count":189,"type":20},1000,"5 Years","With the continuous development of China's economy and the improvement of medical standards, the life expectancy of the Chinese population has significantly increased. Against the backdrop of accelerating aging in China, the incidence of age-related chronic non-communicable diseases (NCDs), such as cardiovascular and cerebrovascular diseases and chronic respiratory diseases, has risen remarkably. These diseases are characterized by multiple comorbidities, high disability rates, and high mortality rates, severely compromising the quality of life of older adults, exacerbating family burdens, and straining healthcare systems. This constitutes one of the major challenges faced by aging societies. Therefore, early detection and intervention of chronic diseases in older adults are critical measures to address population aging.\n\nComprehensive geriatric assessment (CGA), a core specialty of geriatric medicine, serves as a fundamental framework for the clinical identification of geriatric syndromes and multidisciplinary management. It is emerging as a key pathway to promote \"healthy aging.\" Guided by this premise, this study aims to explore the application value of CGA in managing chronic diseases among older adults, with the goal of achieving full-cycle management for early detection, diagnosis, and treatment of chronic conditions in China's elderly population.",[193,194,195],"Comprehensive Geriatric Assessment","Chronic Disease Management","Older Adults (65 Years and Older)",[193,194,197],"Older Adults","2025-06-14",{"date":200,"type":44},"2025-06-24",{"date":202,"type":20},"2025-07-01",{"date":204,"type":20},"2030-05-01",{"name":50,"class":51},{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":16,"minAge":213,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":64,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":4},"100587515","comparing-btva-and-mwa-in-copd-with-early-lung-cancer-efficacy-and-safety-100587515","NCT06929390","Comparing BTVA and MWA in COPD With Early Lung Cancer: Efficacy and Safety","A Prospective, Multicenter, Randomized Controlled Clinical Trial Comparing Bronchoscopic Thermal Vapor Ablation and Percutaneous Microwave Ablation in Patients With COPD and Early-Stage Lung Cancer: Efficacy and Safety Evaluation","Inclusion Criteria:\n\nSubjects meeting all of the following criteria are eligible for inclusion:\n\n1. Patients of any gender aged between 35 and 80 years with a diagnosis of chronic obstructive pulmonary disease (COPD);\n2. Chest CT showing ground-glass nodules (GGNs) with a solid\u002Ftumor ratio (CTR) ≤ 0.25;\n3. Nodule size \\\u003C 2cm located in the upper lobes of both lungs;\n4. Pathologically diagnosed as primary peripheral lung cancer, with preoperative clinical staging indicating T1a, bN0M0;\n5. Investigator assessment that ablative techniques can be feasibly implemented via bronchoscopic or percutaneous approaches to reach the lesion;\n6. Patients unable to undergo surgery or refuse surgery and are unwilling or intolerant to radiation or chemotherapy;\n7. Signing an informed consent form, understanding, and actively cooperating with follow-up procedures\n\nExclusion Criteria:\n\nSubjects meeting any of the following conditions are ineligible for inclusion:\n\n1. Bronchoscopy contraindications, such as:\n\n   1. Myocardial infarction within the past month, unstable myocardial ischemia, ejection fraction (EF) ≤40%\n   2. Active hemoptysis\n   3. Coagulation disorders\n   4. Severe hepatic, renal, cardiac, pulmonary, or cerebral dysfunction, severe anemia, dehydration, and severe nutritional disturbances that cannot be corrected or improved in the short term\n2. Pulmonary function reports indicating FEV1 ≤ 20% predicted value, or DLCO ≤ 20%;\n3. Respiratory tract infection or acute exacerbation of chronic obstructive pulmonary disease within the preceding 6 weeks before screening;\n4. Presence of large bullae in the lobe containing the target lung segment\u002Fsubsegment (defined as bullae occupying more than 1\u002F3 of the lobe) or paraseptal emphysema;\n5. High-density emphysematous changes simultaneously present in the upper and lower lobes of the contralateral lung, defined as HRCT showing low attenuation areas (\\\u003C-950 HU) comprising more than 40% of the total lung volume;\n6. Tumor located within 2cm of the trachea, main bronchi, esophagus, aortic arch branches, main pulmonary artery, left and right pulmonary arteries, or heart, and within 1cm of the nearest pleural boundary;\n7. Active pathogenic infection or evidence of active infection (e.g., fever, elevated white cell count), poorly controlled infectious or inflammatory conditions around the lesion or at the puncture site;\n8. Discontinuation of anticoagulant and\u002For antiplatelet medications (excluding new oral anticoagulants such as dabigatran, rivaroxaban) for less than 5-7 days before surgery;\n9. Coexisting conditions or medication use increasing the risk of post-treatment complications, including but not limited to: autoimmune disorders, clinically significant immunosuppressants, history of asthma, α-1 antitrypsin deficiency;\n10. Daily prednisolone intake exceeding 10mg or an equivalent dose of glucocorticoids during the screening visit;\n11. History of cardiac or pulmonary transplantation, surgical lung volume reduction, median sternotomy, endoscopic lung volume reduction (e.g., valves, coils), lobectomy, or lung resection;\n12. Eastern Cooperative Oncology Group (ECOG) score \\>2;\n13. Participation in or currently involved in other clinical studies within the past 30 days;\n14. Other conditions deemed unsuitable for participation by the investigator.","35 Years","80 Years",{"count":216,"type":20},26,[66],"Based on the advantages of BTVA in the treatment of early-stage lung cancer and COPD, researchers propose the concept of using BTVA to treat COPD combined with early-stage lung cancer. Researchers plan to conduct a multicenter clinical study focusing on patients with COPD combined with malignant GGNs. Bronchoscopic BTVA surgery or percutaneous MWA surgery will be performed, evaluating the effectiveness and safety of bronchoscopic BTVA and percutaneous MWA surgery in the treatment of COPD combined with early-stage lung cancer.",[220,221],"Copd","Lung Cancer","2025-04-15",{"date":224,"type":44},"2025-04-18",{"date":226,"type":20},"2025-05-01",{"date":228,"type":20},"2028-12-31",{"name":50,"class":51},{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":4},"100581707","prediction-model-for-delayed-extubation-of-tracheal-intubation-in-patients-with-maxillofacial-space-infection-after-abscess-incision-and-drainage-surgery-100581707","NCT06853808","Prediction Model for Delayed Extubation of Tracheal Intubation in Patients With Maxillofacial Space Infection After Abscess Incision and Drainage Surgery","Prediction mod","Inclusion Criteria:\n\n* Age ≥ 18 years old (actual age of the patient)\n* Patients diagnosed with maxillofacial space infection upon admission\n\nExclusion Criteria:\n\n* Serious errors or omissions in key demographic information and medical records",{"count":238,"type":20},400,"Retrospective exploration of the risk factors associated with mechanical ventilation and tracheal extubation twenty-four hours after abscess incision and drainage surgery in patients with maxillofacial space infection.",[241],"Oral Infection",[243],"oral infection","2025-02-28",{"date":246,"type":44},"2025-03-03",{"date":248,"type":20},"2025-02-25",{"date":250,"type":20},"2025-12-31",{"name":50,"class":51},{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":112,"sex":16,"minAge":258,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":64,"phases":261,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":4},"100567446","clinical-study-of-g-protein-biased----opioid-receptor-agonist-oliceridine-for-optimizing-postoperative-analgesia-under-general-anesthesia-100567446","NCT06668298","Clinical Study of G Protein Biased Μ - Opioid Receptor Agonist Oliceridine for Optimizing Postoperative Analgesia Under General Anesthesia","Inclusion Criteria:\n\n1. Age\\>65 years old\n2. ASA Level I-III\n3. BMI 18.5-29.9\n4. Patients undergoing knee joint surface replacement surgery under general anesthesia\n5. Postoperative Patient Controlled Intravenous Analgesia Pump (PCIA) Treatment\n6. Possess reading and writing abilities\n7. You can sign an informed consent form\n\nExclusion Criteria:\n\n1. Suffering from chronic pain or mental illness before surgery\n2. Unable to communicate due to cognitive impairment or language barriers before surgery\n3. Patients who have used opioid drugs three days before surgery\n4. Patients with long-term alcohol consumption\n5. Abnormal liver and kidney function or dialysis patients\n6. Concurrent severe cardiovascular, respiratory, and autonomic neuropathy\n7. Participated in clinical studies of other drugs or medical devices in the past 3 months","65 Years",{"count":260,"type":20},150,[66],"Traditional opioid analgesia is a treatment method for moderate to severe pain. However, the use of opioid drugs is not without risks. When treating acute pain, patients may experience hypotension, respiratory depression, hypoxia, nausea and vomiting, irritability, and itching. The purpose of this study is to evaluate the comparison of G protein biased μ - opioid receptor agonist oliceridine and traditional μ - opioid receptor agonist sufentanil in terms of analgesia in patients under general anesthesia.",[264],"Old Age",[266,267,268],"old age","knee arthroplasty","pain","2024-10-30",{"date":271,"type":44},"2024-10-31",{"date":273,"type":20},"2024-11",{"date":275,"type":20},"2025-06",{"name":50,"class":51},{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":258,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":64,"phases":285,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":52},"100557812","effect-of-prophylactic-application-of-40hz-transcranial-stimulation-in-aicu-on-incidence-of-postoperative-delirium-in-elderly-patients-undergoing-elective-gastrointestinal-surgery-100557812","NCT06542978","Effect of Prophylactic Application of 40Hz Transcranial Stimulation in AICU on Incidence of Postoperative Delirium in Elderly Patients Undergoing Elective Gastrointestinal Surgery","Inclusion Criteria:\n\n* 1.Age ≥ 65 years old,gender not limited\n* 2.ASA classification Ⅱ \\~ Ⅳ\n* 3.Elective gastrointestinal general anesthesia surgery\n\nExclusion Criteria:\n\n* 1.History of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis\n* 2.Pre-operative coma, severe dementia, speech impairment or severe illness incapacitated and unable to communicate\n* 3.Delirium on admission or pre-operative delirium, brain injury\n* 4.Severely infected person\n* 5.Severe liver dysfunction (Child-Pugh C), severe renal insufficiency (preoperative dialysis)\n* 6.Severe hearing or vision impairment",{"count":284,"type":20},98,[66],"Postoperative delirium is an acute central nervous system dysfunction caused by surgical stress, which is manifested by postoperative acute, non-specific changes in consciousness level, attention, cognitive ability and disturbance of sleep and wake cycles. It is one of the most common surgical complications in the elderly, occurring in more than 75% of patients receiving mechanical ventilation in the intensive care unit(ICU).Exogenous 40 Hz stimulation can improve cognitive functioning.Therefore, the aim of this study was to investigate the effect of exogenous 40Hz stimulation on the incidence of postoperative delirium in elderly patients undergoing elective gastrointestinal surgery in AICU.",[288,289,290],"Postoperative Delirium","Anesthesia","Elderly","2024-10-24",{"date":293,"type":44},"2024-10-28",{"date":295,"type":44},"2024-05-01",{"date":297,"type":20},"2025-03-01",{"name":50,"class":51},{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":112,"sex":89,"minAge":17,"maxAge":214,"enrollmentInfo":305,"targetDuration":4,"studyType":64,"phases":307,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":319,"leadSponsor":320,"locationsCount":52},"100559325","the-effect-of-mask-combined-with-high-flow-oxygen-on-preoxygenation-during-induction-of-general-anesthesia-in-obese-patients-100559325","NCT06562660","The Effect of Mask Combined With High Flow Oxygen on Preoxygenation During Induction of General Anesthesia in Obese Patients","Inclusion Criteria:\n\n1. Participants ranged in age from 18 to 80 with BMI≥30 kg\u002Fm2.\n2. Participants are male obese patients undergoing elective non-thoracic surgery\n\nExclusion Criteria :\n\n1. patients were kept awake during the intubation due to cervical spine pathology.\n2. Patients with unstable hemodynamics.\n3. Patients with airway inflammatory diseases, including asthma, chronic obstructive pulmonary disease (COPD), lung cancer, pulmonary fibrosis and cystic fibrosis.\n4. Patients with upper respiratory infection and nasal blockage.\n5. Patients with Hypersensitivity to the drug.",{"count":306,"type":20},60,[66],"There is a risk of airway-related incidents during anaesthesia associated with obesity. High-flow nasal oxygen is advocated for perioperative preoxygenation in obese patients to reduce airway adverse reactions. However, there have been no reports on whether smoking behaviors have an impact on obese men's Apnoeic oxygenation with high-flow nasal.This study compared the effects of smoking on the duration of safe apnoea times in obese males.",[310],"Obese",[312,313,314],"High-Flow Nasal Oxygen","Obese Men","Smoking","2024-09-18",{"date":317,"type":44},"2024-09-20",{"date":295,"type":44},{"date":297,"type":20},{"name":50,"class":51},{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":61,"enrollmentInfo":328,"targetDuration":4,"studyType":64,"phases":330,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":4},"100561297","phase-2-btla-inhibitor-js004-combined-with-toripalimab-and-chemotherapy-in-the-perioperative-treatment-of-resectable-locally-advanced-thoracic-esophageal-squamous-cell-carcinoma-100561297","NCT06588335","BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma","A Single-Center, Exploratory Study of BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. The patient voluntarily participates in this study, signs the informed consent form, has good compliance, and cooperates with the follow-up;\n2. Age 18-75 years old, including 18 and 75 years old, both male and female;\n3. Histologically or cytologically confirmed clinical stage of locally advanced (T1N1-3M0 or T2-3N0-3M0) thoracic esophageal squamous cell carcinoma (8th UICC-TNM staging);\n4. Enhanced CT of the neck shows no suspicious metastatic lymph nodes (excluding lymph nodes in the esophageal cancer area), and imaging examination shows no distant metastasis;\n5. ECOG: 0\\~1 score;\n6. Expected to achieve R0 resection;\n7. No previous anti-tumor treatment for esophageal cancer, including chemotherapy, radiotherapy (including planned radiotherapy during the study period), hormone therapy and immunotherapy;\n8. Have measurable lesions or assessable non-measurable lesions (according to RECIST 1.1 criteria);\n9. The function of important organs meets the following requirements (no use of any blood components and cell growth factors is allowed within 2 weeks before the screening examination): a. Absolute neutrophil count (ANC) ≥1.5×10\\^9\u002FL; b. Platelets ≥100×10\\^9\u002FL; c. Hemoglobin ≥90g\u002FdL; d. Serum albumin ≥2.8g\u002FdL; e. Total bilirubin ≤1.5×ULN, ALT, AST and\u002For AKP ≤2.5×ULN; f. Serum creatinine ≤1.5×ULN or creatinine clearance ≥60mL\u002Fmin (calculated by Cockcroft-Gault formula); g. International Normalized Ratio (INR) and Activated Partial Thromboplastin Time (APTT) ≤1.5×ULN (for those using a stable dose of anticoagulant therapy such as low molecular weight heparin or warfarin, and the INR is within the expected therapeutic range of the anticoagulant, they can be screened);\n10. For female subjects of childbearing potential, a urine or serum pregnancy test must be performed within 72 hours prior to receiving the first study drug, and the result must be negative, and they are willing to use effective contraception during the study period and for 6 months after the last dose.\n\nExclusion Criteria:\n\n1. Patients at high risk of gastrointestinal bleeding, esophageal fistula, or esophageal perforation.\n2. Patients with uncontrolled, recurrent pleural effusion, pericardial effusion, or ascites requiring repeated drainage.\n3. Patients with severe dysfunction of the heart, lung, liver, kidney, hematopoietic system, endocrine system, or cachexia.\n4. Patients who have received any of the following treatments: a. Major surgery (except for diagnostic tissue biopsy) or serious trauma within 4 weeks prior to first study drug administration. b. Anti-cancer therapy (including chemotherapy, radiotherapy, immunotherapy, targeted therapy, biotherapy, or tumor embolization) within 4 weeks prior to first study drug administration. c. Any investigational drug within 4 weeks prior to first study drug administration. d. Anti-cancer vaccine or live vaccine within 4 weeks prior to first study drug administration. e. Systemic corticosteroid therapy (\\>10 mg prednisone equivalent per day) or other immunosuppressants within 2 weeks prior to first study drug administration, except for local inflammation of the esophagus and prevention of allergy and nausea\u002Fvomiting.\n5. Patients whose previous anti-cancer therapy toxicity has not recovered to ≤CTCAE Grade 1 (except for alopecia).\n6. Patients with sodium, potassium, or calcium laboratory abnormalities \\>Grade 1 that cannot be corrected within 2 weeks prior to first study drug administration.\n7. Patients with any active autoimmune disease or history of autoimmune disease (e.g., interstitial pneumonitis, uveitis, colitis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism), except for vitiligo or childhood asthma\u002Fallergy that has resolved without the need for intervention in adulthood.\n8. Patients with a history of immunodeficiency, including HIV-positive, other acquired or congenital immunodeficiency disorders, organ transplant, or allogeneic bone marrow transplant.\n9. Patients with uncontrolled cardiac conditions, such as (1) NYHA Class II or higher heart failure, (2) unstable angina, (3) myocardial infarction within 1 year, or (4) clinically significant arrhythmias requiring intervention.\n10. Patients with a serious infection (CTCAE \\>Grade 2) within 4 weeks prior to first study drug administration, active lung inflammation on baseline imaging, or symptoms\u002Fsigns of infection within 2 weeks prior to first study drug administration requiring oral or IV antibiotics (except for prophylactic use).\n11. Patients with active hepatitis B (HBV DNA ≥ 2000 IU\u002FmL or 104 copies\u002FmL) or active hepatitis C (positive HCV antibody and detectable HCV-RNA).\n12. Patients with known hypersensitivity, allergy, or contraindication to JS004, toripalimab, or any of their formulation components.\n13. Patients with any other malignancy, except for low-risk malignancies (5-year survival rate \\>90%) such as fully treated basal cell or squamous cell skin cancer or cervical carcinoma in situ.\n14. Pregnant or breastfeeding women, or patients of reproductive potential unwilling or unable to use effective contraception.\n\nThe investigator may also exclude patients if there are other factors that may lead to premature discontinuation from the study, such as other serious concurrent illnesses (including psychiatric disorders) requiring concomitant treatment, high risk of recurrence of recent serious illness (e.g., myocardial infarction, stroke), severe laboratory abnormalities, or family\u002Fsocial factors that may affect patient safety or data collection.",{"count":329,"type":20},20,[331],"PHASE2","This is a single-center, single-arm, phase II study, aiming to preliminarily explore the efficacy and safety of JS004 combined with toripalimab and chemotherapy for perioperative treatment of locally advanced thoracic esophageal squamous cell carcinoma that is resectable. The plan is to enroll 20 patients with locally advanced resectable thoracic esophageal cancer. In the neoadjuvant treatment phase, patients will receive JS004 + toripalimab + chemotherapy (paclitaxel + cisplatin) for 2 cycles. This will be followed by the surgical phase: surgery will be performed 3-8 weeks after the last dose of neoadjuvant treatment. In the postoperative maintenance treatment phase, maintenance treatment will start 4 weeks ± 7 days after surgery, but no later than 10 weeks after surgery. For patients with R0 resection confirmed by postoperative pathology, they will receive maintenance treatment with JS004 + toripalimab for up to 15 cycles. For patients with non-R0 resection, they will receive maintenance treatment with JS004 + toripalimab combined with standard radiation or chemotherapy (selected by the investigator based on esophageal cancer guidelines). During the study, the maximum number of cycles of JS004 combined with toripalimab is 17 cycles (approximately 1 year).",[334],"Esophageal Squamous Cell Carcinoma","2024-09-10",{"date":337,"type":44},"2024-09-19",{"date":339,"type":20},"2024-09-30",{"date":341,"type":20},"2026-09-30",{"name":50,"class":51},{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":16,"minAge":258,"maxAge":350,"enrollmentInfo":351,"targetDuration":4,"studyType":64,"phases":353,"briefSummary":354,"conditions":355,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":360,"leadSponsor":362,"locationsCount":52},"100556206","the-effect-of-40-hz-transcranial-stimulation-on-the-incidence-of-delirium-after-total-hip-replacement-or-total-knee-replacement-arthroplasty-in-elderly-patients-100556206","NCT06522087","The Effect of 40 Hz Transcranial Stimulation on the Incidence of Delirium After Total Hip Replacement or Total Knee Replacement Arthroplasty in Elderly Patients.","The Effect of 40 Hz Transcranial Stimulation on the Incidence of Delirium After Total Hip Replacement or Total Knee Replacement Arthroplasty in Elderly Patients","Inclusion Criteria:\n\n1.65-85 years old, gender not limited 2.General anesthesia unilateral total hip replacement surgery or unilateral total knee replacement 3.ASA classification I-III 4.No drugs for mental and central nervous system diseases were used before surgery 5.Preoperative MMSE score illiterate \\> 17 points, primary \\> 20 points, junior high school and above \\> 24 points 6.Obtaining informed consent\n\nExclusion Criteria:\n\n1. Severe liver and kidney dysfunction\n2. here were mental and nervous system diseases before operation\n3. Have a history of alcoholism, long-term use of sedative or analgesic\n4. A history of a delirium and other reasons are reluctant to cooperate\n5. Massive blood loss and blood transfusion during operation, prolonged operation time","85 Years",{"count":352,"type":20},110,[66],"Delirium is an acute confusional state, it is a sign of acute encephalopathy, also known as acute brain failure, acute brain dysfunction or mental state changes.Postoperative delirium can cause post-traumatic stress disorder, affects patients' quality of life, extend the length of hospital stay, increased hospitalization cost, and is closely relative to short-term and long-term mortality after surgery. Exogenous 40 Hz stimulation can improve cognitive functioning. Therefore, the aim of this study was to investigate the effect of exogenous 40Hz stimulation on the incidence of postoperative delirium in elderly patients undergoing hip and knee replacement.",[288,289,290],"2024-08-26",{"date":358,"type":44},"2024-08-28",{"date":295,"type":44},{"date":361,"type":20},"2025-03-15",{"name":50,"class":51},{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":214,"enrollmentInfo":369,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":370,"conditions":371,"keywords":373,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":52},"100527295","application-value-of-whole-procedure-optimization-for-catheter-ablation-of-atrial-fibrillation-100527295","NCT06145906","Application Value of Whole-procedure Optimization for Catheter Ablation of Atrial Fibrillation","Inclusion Criteria:\n\n* Radiofrequency catheter ablation for the first time\n* AF rhythm recorded by ECG\n\nExclusion Criteria:\n\n* Thrombosis in left atrium\n* Left ventricular ejection fraction of \\\u003C 35%\n* Abnormal thyroid function\n* Previous history of AF radiofrequency ablation and CABG\n* Left atrium diameter of \\> 65 mm or the volume of \\> 200 ml",{"count":238,"type":20},"The success rate of single-procedure atrial arrhythmia-free survival particularly ranged from 40% to 66% in persistent AF ablation. However, The surgical Cox maze III procedure has been established to be an effective curative strategy for AF with an AF-free survival rate of more than 95%. The main reason is the difficulty of creating continuous, transmural, and durable lesions by catheter ablation, especially when the procedure is performed on some complex anatomical structures in which epicardial muscular bundles may serve as components of the reentrant circuits.\n\nThe durability of the conduction block is a crucial factor for long-term effective AF ablation since previous studies reported that the reconnected Pulmonary veins contributed to the atrial tachycardia recurrence after persistent AF ablation. In addition, it is possible that the inadequate lesions accidentally produce new arrhythmogenic substrates. Therefore, new and better techniques are always chosen to minimize the reconnection of Pulmonary vein isolation (PVI) and additional ablation.\n\nFor paroxysmal AF, the ablation strategy of PVI plus superior vena cava isolation is chosen while PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus (CTI) for persistent AF. Any symptomatic or asymptomatic atrial arrhythmia lasting more than 30 seconds was regarded as an AF recurrence after a 3-month blanking period. The primary outcome was defined as 12-month atrial arrhythmia-free survival. The secondary outcomes include the block rate of PVI, superior vena cava isolation, and all linear ablations.",[372],"Atrial Fibrillation",[374,375,376],"atrial fibrillation","catheter ablation","optimized strategies and workflows","2024-03-15",{"date":379,"type":44},"2024-03-18",{"date":381,"type":44},"2023-12-26",{"date":383,"type":20},"2026-12-01",{"name":50,"class":51},{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":64,"phases":394,"briefSummary":395,"conditions":396,"keywords":4,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":52},"100480768","phase-2-tislelizumab-one-anti-pd-1-antibody-plus-low-dose-bevacizumab-for-bevacizumab-refractory-recurrent-glioblastoma-100480768","NCT05540275","Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma","Phase 2 Study to Evaluate the Clinical Efficacy and Safety of Tislelizumab Plus Low-dose Bevacizumab in Bevacizumab Refractory Recurrent Glioblastoma With PTEN or TERT Gene Mutations","Inclusion Criteria:\n\n1. Written informed consent and HIPAA authorization obtained from the subject\u002Flegal representative prior to performing any protocol-related procedures, including screening evaluations\n2. Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of thestudy, including disease assessment by MRI and tumor in situ fluid (TISF) collection\n3. Histologically confirmed diagnosis of glioma\n4. Resection surgery done at the study center (Henan Provincial People'sHospital), with an reservoir intraoperatively implanted connecting the surgical cavity and the subscalp for postoperative noninvasive TISF collection\n5. An interval of \\> 28 days and full recovery (i.e., no ongoing safety issues) from surgical resection prior to grouping\n6. Karnofsky performance status (KPS) of 70 or higher\n7. Life expectancy \\> 12 weeks\n\nExclusion Criteria:\n\n1. More than two recurrences of GBM\n2. Presence of extracranial metastatic, significant leptomeningeal disease or tumors primarily localized to the brainstem or spinal cord\n3. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results\n4. Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring chronic and systemic immunosuppressive treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Subjects have any other condition requiring systemic treatment with corticosteroids or other immunosuppressive agents within 14 days. Inhaled or topical steroids and adrenal replacement doses \\>10mg daily prednisone equivalent are permitted in absence of active autoimmune disease\n5. Previous radiation therapy with anything other than standard radiation therapy (i.e., focally directed radiation) administered as first line therapy\n6. Previous treatment with carmustine wafer except when administered as first line treatment and at least 6 months prior to randomization\n7. Previous bevacizumab or other VEGF or anti-angiogenic treatment\n8. Previous treatment with a PD-1, PD-L1 or CTLA-4 targeted therapy\n9. Evidence of \\> Grade 1 CNS hemorrhage on the baseline MRI scan\n10. Inadequately controlled hypertension (defined as systolic blood pressure ≥160 mmHg and \u002For diastolic blood pressure ≥100 mmHg) within 7 days of first study treatment\n11. Prior history of hypertensive crisis, hypertensive encephalopathy, reversible posterior leukoencephalopathy syndrome (RPLS)\n12. Prior history of gastrointestinal diverticulitis, perforation, or abscess\n13. Clinically significant (i.e., active) cardiovascular disease, for example cerebrovascular accidents ≤ 6 months prior to study enrollment, myocardial infarction ≤ 6 months prior to study enrollment, unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment\n14. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to start of study treatment. Any previous venous thromboembolism ≥ NCI CTCAE Grade 3 within 3 months prior to start of study treatment\n15. History of pulmonary hemorrhage\u002Fhemoptysis ≥ grade 2 (defined as ≥ 2.5 mL bright red blood per episode) within 1 month prior to randomization\n16. History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation)\n17. Current or recent (within 10 days of study enrollment) use of anticoagulants that, in the opinion of the investigator, would place the subject at significant risk for bleeding. Prophylactic use of anticoagulants is allowed\n18. Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to first study treatment, or anticipation of need for major surgical procedure during the course of the study\n19. Minor surgical procedure (e.g., stereotactic biopsy within 7 days of first study treatment; placement of a vascular access device within 2 days of first study treatment)\n20. History of intracranial abscess within 6 months prior to randomization\n21. History of active gastrointestinal bleeding within 6 months prior to randomization",{"count":393,"type":20},30,[331],"The purpose of this study is to evaluate the clinical efficacy and safety of Tislelizumab (one anti-PD-1 antibody same as nivolumab approved in China) in combination with bevacizumab in patients with recurrent or progressive glioblastoma (GBM) who have progressed on bevacizumab with or without PTEN or TERT gene mutations.",[397],"Recurrent Glioblastoma","2023-10-04",{"date":400,"type":44},"2023-10-06",{"date":402,"type":20},"2023-10-05",{"date":404,"type":20},"2026-12",{"name":50,"class":51},{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":61,"enrollmentInfo":413,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":414,"conditions":415,"keywords":417,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":52},"100480206","correlation-between-psychological-stress-and-progression-of-diffuse-astrocytoma-towards-secondary-glioma-100480206","NCT05532969","Correlation Between Psychological Stress and Progression of Diffuse Astrocytoma Towards Secondary Glioma","Correlation Between Psychological Stress and Progression of Diffuse Astrocytoma Towards Secondary Glioma: a Longitudinal Study Based on Long-term Follow-up","Inclusion Criteria:\n\n* age ≥18 years\n* Karnofsky Performance Score ≥ 70 %\n* histologically confirmed, previously untreated glioma\n* receiving a standardized chemoradiotherapy regimen\n* no previous history of mental illness, drug abuse, or alcohol abuse\n* ability to communicate and read and write independently\n* willing and able to comply with the protocol as judged by the investigator's signed informed consent.\n\nExclusion Criteria:\n\n* Patients who have any other disease, either metabolic or psychological, or who have any evidence on clinical examination or special investigations (including laboratory findings) which give reasonable suspicion of a condition that interferes with the adequate measurement of the stress axis (e.g. chronic use of corticosteroids ≥ 3 months before study entry for diseases other than glioblastoma, (dexamethasone use in the context of glioblastoma is allowed) severe, medically treated psychiatric disorder prior to the diagnosis of glioblastoma Participation in a study with investigational drugs.\n* pregnancy or breast-feeding\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurologic deficits that interfere with the planned walking tests, dementia, or confusional state.",{"count":306,"type":20},"It is a single-center, prospective, observational, non-randomized study of newly diagnosed diffuse astrocytoma patients conducted in a tertiary hospital. The investigators conduct an eight-year follow-up, including patients' psychological stress, immune biomarker changes, quality of life, and disease progression of patients towards secondary glioma after the first definite diagnosis. In the first year after diagnosis, patients are followed up four times at 1 month, 3 months, 6 months, and 12 months. After that, patients are followed up semiannually.\n\nThe study had two cohorts, a high-stress cohort and a low-stress cohort, which are grouped after initial recruitment. Both groups undergo total resection of tumors and received 3 months of standardized treatment with radiotherapy and chemotherapy. Neither participants nor doctors but the researcher can choose which group participants are in. No one knows if one study group is better or worse than the other.",[416],"Astrocytoma",[416,418,419],"Psychological stress","progression","2022-09-25",{"date":422,"type":44},"2022-09-27",{"date":424,"type":20},"2022-12-20",{"date":426,"type":20},"2026-12-20",{"name":50,"class":51},{"id":429,"slug":430,"hasResults":11,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":61,"enrollmentInfo":435,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":436,"conditions":437,"keywords":439,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":441,"startDateStruct":442,"completionDateStruct":443,"leadSponsor":445,"locationsCount":4},"100480515","correlation-between-psychological-stress-and-progression-of-newly-oligodendroglioma-towards-secondary-glioma-100480515","NCT05536986","Correlation Between Psychological Stress and Progression of Newly Oligodendroglioma Towards Secondary Glioma","Correlation Between Psychological Stress and Progression of Newly Oligodendroglioma Towards Secondary Glioma: A Longitudinal Study Based on Long-term Follow-up","Inclusion Criteria:\n\n* age ≥18 years\n* Karnofsky Performance Score ≥ 70 %\n* histologically confirmed, previously untreated glioma receiving a standardized chemoradiotherapy regimen\n* no previous history of mental illness, drug abuse, or alcohol abuse\n* ability to communicate and read and write independently\n* willing and able to comply with the protocol as judged by the investigator's signed informed consent.\n\nExclusion Criteria:\n\n* Patients who have any other disease, either metabolic or psychological, or who have any evidence on clinical examination or special investigations (including laboratory findings) which give reasonable suspicion of a condition that interferes with the adequate measurement of the stress axis (e.g. chronic use of corticosteroids ≥ 3 months before study entry for diseases other than glioblastoma, (dexamethasone use in the context of glioblastoma is allowed) severe, medically treated psychiatric disorder prior to the diagnosis of glioblastoma Participation in a study with investigational drugs.\n* pregnancy or breast-feeding\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurologic deficits that interfere with the planned walking tests, dementia, or confusional state.",{"count":306,"type":20},"It is a single-center, prospective, observational, non-randomized study of newly diagnosed oligodendroglioma patients conducted in a tertiary hospital. The investigators conduct an eight-year follow-up, including patients' psychological stress, immune biomarker changes, quality of life, and disease progression of patients towards secondary glioma after the first definite diagnosis. In the first year after diagnosis, patients are followed up four times at 1 month, 3 months, 6 months, and 12 months. After that, patients are followed up semiannually.\n\nThe study had two cohorts, a high-stress cohort and a low-stress cohort, which are grouped after initial recruitment. Both groups undergo total resection of tumors and received 3 months of standardized treatment with radiotherapy and chemotherapy. Neither participants nor doctors but the researcher can choose which group participants are in. No one knows if one study group is better or worse than the other.",[438],"Oligodendroglioma, Adult",[440,418,419],"Oligodendroglioma",{"date":422,"type":44},{"date":424,"type":20},{"date":444,"type":20},"2030-12-20",{"name":50,"class":51},{"id":447,"slug":448,"hasResults":11,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":61,"enrollmentInfo":453,"targetDuration":190,"studyType":21,"phases":4,"briefSummary":455,"conditions":456,"keywords":458,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":460,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":464,"locationsCount":52},"100478619","study-on-gene-evolution-in-glioma-under-stress-therapy-100478619","NCT05512325","Study on Gene Evolution in Glioma Under Stress Therapy","Study on Gene Evolution and Anti-VEGF Treatment Response of Different Subtypes of Glioma Based on ctDNA","Inclusion Criteria:\n\n* Age 18 to 75 years, both male and female (including 18 and 75 years old) glioma;\n* Willing to accept treatment and sign informed consent.\n\nExclusion Criteria:\n\n* Participants with other infection disease or immunodeficiency disease;\n* other central infectious diseases;\n* malignant tumor of non-nervous system;\n* drug abuse;\n* severe psychiatric disease;\n* uncontrolled diabetes;",{"count":454,"type":20},100,"Little is known about the evolution of genetic and epigenetic changes that occur in the progression of glioma. We inferred the evolution trajectories of matched pairs of primary tumors and progression tumor in situ fluid (TISF) based on deep whole-genome-sequencing data (ctDNA). A monocentric, Gene grouping controlled trial design was used to select patients. and to compare gene evolution of different subtypes of glioma under therapy. To predict the molecular reaction of bevacizumab treatment, clarify the mechanism of drug resistance of bevacizumab treatment.",[457],"Genetic Change",[459],"gene evolution, ctDNA, molecular response, Bevacizumab",{"date":422,"type":44},{"date":462,"type":20},"2022-12-17",{"date":104,"type":20},{"name":50,"class":51},{"id":466,"slug":467,"hasResults":11,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":477,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":52},"100480827","radiogenomics-in-glioblastoma-correlation-between-multiparametric-imaging-biomarkers-and-genetic-biomarkers-100480827","NCT05541042","Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers","Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers Based on Tumor Tissues and ctDNA","Inclusion Criteria:\n\n* Written informed consent and HIPAA authorization obtained from the subject\u002Flegal representative prior to performing any protocol-related procedures, including screening evaluations\n* Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study\n* Histologically confirmed diagnosis of glioblastoma\n* Resection surgery done at the study center (Henan Provincial People's Hospital), with an reservoir intraoperatively implanted connecting the surgical cavity and the subscalp for postoperative noninvasive TISF collection\n* Able to tolerable PET\u002FCT and CT imaging required by protocol\n* Karnofsky performance status (KPS) of 70 or higher\n\nExclusion Criteria:\n\n* Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results\n* Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring chronic and systemic immunosuppressive treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Subjects have any other condition requiring systemic treatment with corticosteroids or other immunosuppressive agents within 14 days. Inhaled or topical steroids and adrenal replacement doses \\>10mg daily prednisone equivalent are permitted in absence of active autoimmune disease\n* Clinically significant (i.e., active) cardiovascular disease, for example cerebrovascular accidents ≤ 6 months prior to study enrollment, myocardial infarction ≤ 6 months prior to study enrollment, unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment\n* Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to start of study treatment. Any previous venous thromboembolism ≥ NCI CTCAE Grade 3 within 3 months prior to start of study treatment\n* History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation)\n* Current or recent (within 10 days of study enrollment) use of anticoagulants that, in the opinion of the investigator, would place the subject at significant risk for bleeding.\n* Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)",{"count":473,"type":20},50,"The purpose of this study is to evaluate relationships between multiparametric imaging biomarkers and genetic analysis in glioblastoma patients.",[476],"Glioblastoma",{"date":422,"type":44},{"date":479,"type":20},"2022-12-01",{"date":481,"type":20},"2027-11-01",{"name":50,"class":51},{"id":484,"slug":485,"hasResults":11,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":64,"phases":491,"briefSummary":492,"conditions":493,"keywords":4,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":494,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":52},"100477901","phase-2-sintilimab-one-anti-pd-1-antibody-plus-low-dose-bevacizumab-for-ctdna-level-relapse-and-clinical-relapse-glioblastoma-100477901","NCT05502991","Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma","Phase 2 Study to Evaluate the Clinical Efficacy and Safety of Sintilimab Plus Low-dose Bevacizumab in Patients With Glioblastoma of Different Relapse Stages","Inclusion Criteria:\n\n1. Written informed consent and HIPAA authorization obtained from the subject\u002Flegal representative prior to performing any protocol-related procedures, including screening evaluations\n2. Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study, including disease assessment by MRI and tumor in situ fluid (TISF) collection\n3. Histologically confirmed diagnosis of glioblastoma\n4. Resection surgery done at the study center (Henan Provincial People's Hospital), with an reservoir intraoperatively implanted connecting the surgical cavity and the subscalp for postoperative noninvasive TISF collection\n5. Previous first line treatment with at least radiotherapy before the study treatment\n6. An interval of \\> 28 days and full recovery (i.e., no ongoing safety issues) from surgical resection prior to grouping\n7. Karnofsky performance status (KPS) of 70 or higher\n8. Life expectancy \\> 12 weeks\n\nExclusion Criteria:\n\n1. More than two recurrences of GBM\n2. Presence of extracranial metastatic, significant leptomeningeal disease or tumors primarily localized to the brainstem or spinal cord\n3. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results\n4. Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring chronic and systemic immunosuppressive treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Subjects have any other condition requiring systemic treatment with corticosteroids or other immunosuppressive agents within 14 days. Inhaled or topical steroids and adrenal replacement doses \\>10mg daily prednisone equivalent are permitted in absence of active autoimmune disease\n5. Previous radiation therapy with anything other than standard radiation therapy (i.e., focally directed radiation) administered as first line therapy\n6. Previous treatment with carmustine wafer except when administered as first line treatment and at least 6 months prior to randomization\n7. Previous bevacizumab or other VEGF or anti-angiogenic treatment\n8. Previous treatment with a PD-1, PD-L1 or CTLA-4 targeted therapy\n9. Evidence of \\> Grade 1 CNS hemorrhage on the baseline MRI scan\n10. Inadequately controlled hypertension (defined as systolic blood pressure ≥160 mmHg and \u002For diastolic blood pressure ≥100 mmHg) within 7 days of first study treatment\n11. Prior history of hypertensive crisis, hypertensive encephalopathy, reversible posterior leukoencephalopathy syndrome (RPLS)\n12. Prior history of gastrointestinal diverticulitis, perforation, or abscess\n13. Clinically significant (i.e., active) cardiovascular disease, for example cerebrovascular accidents ≤ 6 months prior to study enrollment, myocardial infarction ≤ 6 months prior to study enrollment, unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment\n14. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to start of study treatment. Any previous venous thromboembolism ≥ NCI CTCAE Grade 3 within 3 months prior to start of study treatment\n15. History of pulmonary hemorrhage\u002Fhemoptysis ≥ grade 2 (defined as ≥ 2.5 mL bright red blood per episode) within 1 month prior to randomization\n16. History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation)\n17. Current or recent (within 10 days of study enrollment) use of anticoagulants that, in the opinion of the investigator, would place the subject at significant risk for bleeding. Prophylactic use of anticoagulants is allowed\n18. Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to first study treatment, or anticipation of need for major surgical procedure during the course of the study\n19. Minor surgical procedure (e.g., stereotactic biopsy within 7 days of first study treatment; placement of a vascular access device within 2 days of first study treatment)\n20. History of intracranial abscess within 6 months prior to randomization;\n21. History of active gastrointestinal bleeding within 6 months prior to randomization\n22. Serious, non-healing wound, active ulcer, or untreated bone fracture\n23. Subjects unable (due to existent medical condition, e.g., pacemaker or ICD device) or unwilling to have a head contrast enhanced MRI\n24. Positive test for hepatitis B virus surface antigen (HBV sAg) or detectable hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection\n25. Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)\n26. History of severe hypersensitivity reaction to any monoclonal antibody\n27. Patients that require decadron \\> 4 mg\u002F day or equivalent of steroids",{"count":306,"type":20},[331],"This is an ongoing Phase 2, open-label, single-center, non-randomized study of sintilimab (one anti-PD-1 antibody same as nivolumab approved in China) plus bevacizumab administered in a low dosage schedule in adult (≥ 18 years) participants with a clinical relapse or circulating tumor DNA (ctDNA)-level relapse of glioblastoma (GBM).\n\nThis study has two non-comparative study groups. Both cohorts will receive the same study drug sintilimab 200mg and bevacizumab 3mg\u002Fkg every 3 weeks. A stringent two-step non-randomized process will be used to assign participants to one of the study groups. Neither participants nor doctors but the researcher can choose which group participants are in. No one knows if one study group is better or worse than the other. 60 total participants are expected to participate in this study (30 participants in each cohort).\n\nGrouping process: After enrollment, under the standard of care, participants will receive regular tumor in situ fluid (fluid within the surgical cavity, TISF) sampling for ctDNA analysis and recceive regular MRI. The researcher will study the TISF ctDNA and imaging dynamics to determine whether the tumor reaches to ctDNA-level (Cohort 1) or clinical relapse (Cohort 2). At the first step, all timely identified as ctDNA-level relapse tumors will be assigned into the Cohort 1 and receive the study drug immediately, those failed to be timely identified will be assigned into the Cohort 2 and receive the study drug after the clinical relapse. At the second step, once either group reaches the target number, the new participants will be all assigned into the other Cohort.",[476],{"date":422,"type":44},{"date":496,"type":20},"2022-12-11",{"date":498,"type":20},"2027-12",{"name":50,"class":51},{"id":501,"slug":502,"hasResults":11,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":64,"phases":508,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":511,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":515,"locationsCount":52},"100478621","phase-2-sintilimab-one-anti-pd-1-antibody-plus-low-dose-bevacizumab-for-ctdnalevel--relapse-and-clinical-relapse-oligodendroglioma-100478621","NCT05512351","Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma","Phase 2 Study to Evaluate the Clinical Efficacy and Safety of Sintilimab Plus Low-dose Bevacizumab in Patients With Oligodendroglioma of Different Relapse Stages","Inclusion Criteria:\n\n1. Written informed consent and HIPAA authorization obtained from the subject\u002Flegal representative prior to performing any protocol-related procedures, including screening evaluations\n2. Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study, including disease assessment by MRI and tumor in situ fluid (TISF) collection\n3. Histologically confirmed diagnosis of oligodendroglioma(WHO III)\n4. Resection surgery done at the study center (Henan Provincial People's Hospital), with an reservoir intraoperatively implanted connecting the surgical cavity and the subscalp for postoperative noninvasive TISF collection\n5. An interval of \\> 28 days and full recovery (i.e., no ongoing safety issues) from surgical resection prior to grouping\n6. Karnofsky performance status (KPS) of 70 or higher\n7. Life expectancy \\> 12 weeks\n\nExclusion Criteria:\n\n1. More than two recurrences of oligodendroglioma\n2. Presence of extracranial metastatic, significant leptomeningeal disease or tumors primarily localized to the brainstem or spinal cord\n3. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results\n4. Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring chronic and systemic immunosuppressive treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Subjects have any other condition requiring systemic treatment with corticosteroids or other immunosuppressive agents within 14 days. Inhaled or topical steroids and adrenal replacement doses \\>10mg daily prednisone equivalent are permitted in absence of active autoimmune disease\n5. Previous radiation therapy with anything other than standard radiation therapy (i.e., focally directed radiation) administered as first line therapy\n6. Previous treatment with carmustine wafer except when administered as first line treatment and at least 6 months prior to randomization\n7. Previous bevacizumab or other VEGF or anti-angiogenic treatment\n8. Previous treatment with a PD-1, PD-L1 or CTLA-4 targeted therapy\n9. Evidence of \\> Grade 1 CNS hemorrhage on the baseline MRI scan\n10. Inadequately controlled hypertension (defined as systolic blood pressure ≥160 mmHg and \u002For diastolic blood pressure ≥100 mmHg) within 7 days of first study treatment\n11. Prior history of hypertensive crisis, hypertensive encephalopathy, reversible posterior leukoencephalopathy syndrome (RPLS)\n12. Prior history of gastrointestinal diverticulitis, perforation, or abscess\n13. Clinically significant (i.e., active) cardiovascular disease, for example cerebrovascular accidents ≤ 6 months prior to study enrollment, myocardial infarction ≤ 6 months prior to study enrollment, unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment\n14. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to start of study treatment. Any previous venous thromboembolism ≥ NCI CTCAE Grade 3 within 3 months prior to start of study treatment\n15. History of pulmonary hemorrhage\u002Fhemoptysis ≥ grade 2 (defined as ≥ 2.5 mL bright red blood per episode) within 1 month prior to randomization\n16. History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation)\n17. Current or recent (within 10 days of study enrollment) use of anticoagulants that, in the opinion of the investigator, would place the subject at significant risk for bleeding. Prophylactic use of anticoagulants is allowed\n18. Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to first study treatment, or anticipation of need for major surgical procedure during the course of the study\n19. Minor surgical procedure (e.g., stereotactic biopsy within 7 days of first study treatment; placement of a vascular access device within 2 days of first study treatment)\n20. History of intracranial abscess within 6 months prior to randomization\n21. History of active gastrointestinal bleeding within 6 months prior to randomization\n22. Serious, non-healing wound, active ulcer, or untreated bone fracture\n23. Subjects unable (due to existent medical condition, e.g., pacemaker or ICD device) or unwilling to have a head contrast enhanced MRI\n24. Positive test for hepatitis B virus surface antigen (HBV sAg) or detectable hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection\n25. Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)\n26. History of severe hypersensitivity reaction to any monoclonal antibody\n27. Patients that require decadron \\> 4 mg\u002F day or equivalent of steroids",{"count":91,"type":20},[331],"This is an ongoing Phase 2, open-label, single-center, non-randomized study of sintilimab (one anti-PD-1 antibody same as nivolumab approved in China) plus bevacizumab administered in a low dosage schedule in adult (≥ 18 years) participants with a clinical relapse or circulating tumor DNA (ctDNA)-level relapse of Oligodendroglioma(WHO III).\n\nThis study has three non-comparative study groups. Cohort 1 and Cohort 2 will receive the same study drug sintilimab 200mg and bevacizumab 3mg\u002Fkg every 3 weeks. Cohort 3 will take only standard treatment. A stringent three-step non-randomized process will be used to assign participants to one of the study groups. Neither participants nor doctors but the researcher can choose which group participants are in. No one knows if one study group is better or worse than the other. 80 total participants are expected to participate in this study (30 participants in Cohort 1 and Cohort 2).\n\nGrouping process: After enrollment, under the standard of care, participants will receive regular tumor in situ fluid (fluid within the surgical cavity, TISF) sampling for ctDNA analysis and recceive regular MRI. The researcher will study the TISF ctDNA and imaging dynamics to determine whether the tumor reaches to ctDNA-level (Cohort 1) or clinical relapse (Cohort 2). At the first step, all timely identified as ctDNA-level relapse tumors will be assigned into the Cohort 1 and receive the study drug immediately, those failed to be timely identified will be assigned into the Cohort 2 and receive the study drug after the clinical relapse. At the second step, once Cohort 1 or Cohort 2 reaches the target number, the new participants will be all assigned into the other Cohort. In the third step, if no CTDNA-level or clinical relapse was observed within 60 months after surgery, patients were assigned to Cohort 3 and further analyzed for prognostic biomarkers compared with Cohort 1 and Cohort 2.",[440],{"date":422,"type":44},{"date":513,"type":20},"2022-12-23",{"date":404,"type":20},{"name":50,"class":51},{"id":517,"slug":518,"hasResults":11,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":523,"targetDuration":4,"studyType":64,"phases":525,"briefSummary":526,"conditions":527,"keywords":4,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":529,"startDateStruct":530,"completionDateStruct":531,"leadSponsor":532,"locationsCount":52},"100479131","phase-2-sintilimab-one-anti-pd-1-antibody-plus-low-dose-bevacizumab-for-ctdnalevel--relapse-and-clinical-relapse-astrocytoma-100479131","NCT05518994","Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma","Phase 2 Study to Evaluate the Clinical Efficacy and Safety of Sintilimab Plus Low-dose Bevacizumab in Patients With Astrocytoma of Different Relapse Stages","Inclusion Criteria:\n\n1. Written informed consent and HIPAA authorization obtained from the subject\u002Flegal representative prior to performing any protocol-related procedures, including screening evaluations\n2. Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study, including disease assessment by MRI and tumor in situ fluid (TISF) collection\n3. Histologically confirmed diagnosis of Astrocytoma\n4. Resection surgery done at the study center (Henan Provincial People's Hospital), with an reservoir intraoperatively implanted connecting the surgical cavity and the subscalp for postoperative noninvasive TISF collection\n5. An interval of \\> 28 days and full recovery (i.e., no ongoing safety issues) from surgical resection prior to grouping\n6. Karnofsky performance status (KPS) of 70 or higher\n7. Life expectancy \\> 12 weeks\n\nExclusion Criteria:\n\n1. More than two recurrences of Astrocytoma\n2. Presence of extracranial metastatic, significant leptomeningeal disease or tumors primarily localized to the brainstem or spinal cord\n3. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results\n4. Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring chronic and systemic immunosuppressive treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Subjects have any other condition requiring systemic treatment with corticosteroids or other immunosuppressive agents within 14 days. Inhaled or topical steroids and adrenal replacement doses \\>10mg daily prednisone equivalent are permitted in absence of active autoimmune disease\n5. Previous radiation therapy with anything other than standard radiation therapy (i.e., focally directed radiation) administered as first line therapy\n6. Previous treatment with carmustine wafer except when administered as first line treatment and at least 6 months prior to randomization\n7. Previous bevacizumab or other VEGF or anti-angiogenic treatment\n8. Previous treatment with a PD-1, PD-L1 or CTLA-4 targeted therapy\n9. Evidence of \\> Grade 1 CNS hemorrhage on the baseline MRI scan\n10. Inadequately controlled hypertension (defined as systolic blood pressure ≥160 mmHg and \u002For diastolic blood pressure ≥100 mmHg) within 7 days of first study treatment\n11. Prior history of hypertensive crisis, hypertensive encephalopathy, reversible posterior leukoencephalopathy syndrome (RPLS)\n12. Prior history of gastrointestinal diverticulitis, perforation, or abscess\n13. Clinically significant (i.e., active) cardiovascular disease, for example cerebrovascular accidents ≤ 6 months prior to study enrollment, myocardial infarction ≤ 6 months prior to study enrollment, unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment\n14. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to start of study treatment. Any previous venous thromboembolism ≥ NCI CTCAE Grade 3 within 3 months prior to start of study treatment\n15. History of pulmonary hemorrhage\u002Fhemoptysis ≥ grade 2 (defined as ≥ 2.5 mL bright red blood per episode) within 1 month prior to randomization\n16. History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation)\n17. Current or recent (within 10 days of study enrollment) use of anticoagulants that, in the opinion of the investigator, would place the subject at significant risk for bleeding. Prophylactic use of anticoagulants is allowed\n18. Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to first study treatment, or anticipation of need for major surgical procedure during the course of the study\n19. Minor surgical procedure (e.g., stereotactic biopsy within 7 days of first study treatment; placement of a vascular access device within 2 days of first study treatment)\n20. History of intracranial abscess within 6 months prior to randomization\n21. History of active gastrointestinal bleeding within 6 months prior to randomization\n22. Serious, non-healing wound, active ulcer, or untreated bone fracture\n23. Subjects unable (due to existent medical condition, e.g., pacemaker or ICD device) or unwilling to have a head contrast enhanced MRI\n24. Positive test for hepatitis B virus surface antigen (HBV sAg) or detectable hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection\n25. Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)\n26. History of severe hypersensitivity reaction to any monoclonal antibody\n27. Patients that require decadron \\> 4 mg\u002F day or equivalent of steroids",{"count":524,"type":20},70,[331],"This is an ongoing Phase 2, open-label, single-center, non-randomized study of sintilimab (one anti-PD-1 antibody same as nivolumab approved in China) plus bevacizumab administered in a low dosage schedule in adult (≥ 18 years) participants with a clinical relapse or circulating tumor DNA (ctDNA)-level relapse of Astrocytoma. This study has three non-comparative study groups. Cohort 1 and Cohort 2 will receive the same study drug sintilimab 200mg and bevacizumab 3mg\u002Fkg every 3 weeks. Cohort 3 will take only standard treatment. A stringent three-step non-randomized process will be used to assign participants to one of the study groups. Neither participants nor doctors but the researcher can choose which group participants are in. No one knows if one study group is better or worse than the other. 70 total participants are expected to participate in this study (25 participants in Cohort 1 and Cohort 2,20 participants in Cohort 3).\n\nGrouping process: After enrollment, under the standard of care, participants will receive regular tumor in situ fluid (fluid within the surgical cavity, TISF) sampling for ctDNA analysis and recceive regular MRI. The researcher will study the TISF ctDNA and imaging dynamics to determine whether the tumor reaches to ctDNA-level (Cohort 1) or clinical relapse (Cohort 2). At the first step, all timely identified as ctDNA-level relapse tumors will be assigned into the Cohort 1 and receive the study drug immediately, those failed to be timely identified will be assigned into the Cohort 2 and receive the study drug after the clinical relapse. At the second step, once Cohort 1 or Cohort 2 reaches the target number, the new participants will be all assigned into the other Cohort. In the third step, if no ctDNA-level or clinical relapse was observed within 60 months after surgery, patients were assigned to Cohort 3 and further analyzed for prognostic biomarkers compared with Cohort 1 and Cohort 2.",[528],"Astrocytoma of Brain",{"date":422,"type":44},{"date":479,"type":20},{"date":498,"type":20},{"name":50,"class":51},{"id":534,"slug":535,"hasResults":11,"nctId":536,"briefTitle":537,"officialTitle":538,"acronym":4,"eligibilityCriteria":539,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":540,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":542,"conditions":543,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":550,"leadSponsor":552,"locationsCount":52},"100468325","noacs-use-in-af-or-vte-sunshine-registry-100468325","NCT05378308","NOACs Use in AF or VTE (SUNSHINE Registry)","Outcomes regiStry for Non-vitamin k Antagonist Oral anticoagUlants treatmeNt in variouS tHrombotIc dIseases for Better cliNical practicE (SUNSHINE)","Inclusion Criteria:\n\n* Patients with clinically diagnosed with AF (eg, by electrocardiogram, Holter monitoring, implanted device, etc) or VTE (initial or recurrent acute VTE)\n* Patients who use OACs therapy (including NOAC or VKA) within the preceding 3 months\n* Patients can be enrolled from both inpatient or outpatient settings\n\nExclusion Criteria:\n\n* AF resulting from reversible cause factors (e.g., thyroid disease, postoperative AF)\n* Patients with a diagnosis of valvular AF (valvular AF mainly refers to patients with AF that have either rheumatic valvular disease \\[predominantly mitral stenosis\\] or mechanical heart valves)\n* Patients participating in an ongoing clinical trial in AF or VTE\n* Have Multiple anticoagulation indications apart from AF or VTE\n* Patients with incomplete information (illogical data, missing or insufficient data)",{"count":541,"type":20},5000,"The outcomes regiStry for non-vitamin k antagonist oral anticoagUlants treatmeNt in variouS tHrombotIc dIseases for better cliNical practicE (SUNSHINE) is a multicenter, prospective, observational non-interventional inpatient\u002Foutpatient disease registry to assess the utilization of Non-vitamin k antagonist oral anticoagulants (NOACs), and associated outcomes. The SUNSHINE registry will focus on the collection and analysis of observational data in medical records from hospital information system (HIS) to evaluate the outcomes related with these NOACs when applied in extensive patient populations outside of clinical research studies. The registry will also allow for mainly combining the atrial fibrillation (AF) and venous thromboembolism (VTE) databases. In brief, the SUNSHINE registry will provide important information on the outcomes of NOACs in routine practice and gather further information on its safety and effectiveness.",[372,544,545],"Venous Thromboembolism","Oral Anticoagulant","2022-06-06",{"date":548,"type":44},"2022-06-09",{"date":546,"type":44},{"date":551,"type":20},"2027-05-31",{"name":50,"class":51},""]